AstraZeneca eyes rare obesity drugmaker in $10B bid
AstraZeneca made a nonbinding offer of about $10 billion to acquire Rhythm Pharmaceuticals, a maker of rare obesity treatments, according to a Nov. 4 Wall Street Journal report. Neither company has confirmed the offer. AstraZeneca made a $124-per-share offer last month, according to the Journal. Rhythm shares closed up 28% at $110.68, giving it a […] The post AstraZeneca eyes rare obesity drugmaker in $10B bid appeared first on Becker's Hospital Review | Healthcare News & Analysis...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.